KPV

KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of α-MSH while lacking its melanogenic (tanning) and hormonal effects. It has shown particular promise for gut inflammation and inflammatory skin conditions.

Penetrates cell membranes and enters the nucleus where it directly inhibits NF-κB activation by preventing IκBα phosphorylation. This blocks production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and inflammatory enzymes (COX-2, iNOS). Can be administered orally (capsule), subcutaneously, or topically. The small tripeptide structure allows GI tract absorption without significant degradation.

Estimated half-life approximately 4 hours based on tripeptide stability. Oral capsule and sublingual forms show GI tissue activity. Subcutaneous injection provides systemic distribution. Anti-inflammatory effects persist beyond plasma clearance due to intranuclear NF-κB modulation.

Inflammatory bowel disease (IBD), ulcerative colitis, gut inflammation, psoriasis and eczema, wound healing, NF-κB inhibition, general anti-inflammatory applications.

Preclinical — published in vitro and animal studies for IBD and skin inflammation. No completed human clinical trials. Available from compounding pharmacies. Growing interest in functional medicine for gut healing protocols.

• KPV anti-inflammatory mechanism — J. Biological Chemistry · doi.org
• α-MSH fragments in IBD — Gut · pubmed.ncbi.nlm.nih.gov
• KPV in colitis models — Peptides · doi.org
• α-MSH fragment stability and bioactivity · doi.org